Somewhat (stock twits)... I think the larger issue is that the intersection of biology and finance doesn't really leave a lot of space for experts on both.

You have plenty of people with a decent grasp on biology going into the Big Pharma / vaccine trades, thinking they're going to make incredible gains, not understanding the market cap / outstanding shares of these behemoths, or that spike proteins on coronaviruses mutate notoriously fast.

You have all the chartists jumping in on anything with momentum and fading blowoff tops, completely ignorant of the companies or their proposed treatments.

You have analysts that can drill down to spot promising candidates, who arbitrage and shift from one to the other as milestones hit or the news cycle shines on one company or the other.

And then you have a bunch of retail investors, who end up somewhere because they like the story... whichever once catches their fancy the most, they generally stick with. HGEN having a Big Pharma link probably makes a large portion of that crowd believe that HGEN is going to have an advantage on a lot of fronts. They aren't wrong per se, but at the end of the day it's clinical outcomes that matter.

Each of those have reason to be coming to CYDY as different camps start to become aware of the likelihood of eventual vaccine failure and competitors dropping out / trial timing in the space. Now is as good a time as any.